Cipla EU to acquire two US pharma companies

Pharmaceutical company Cipla’s UK arm, Cipla EU, has decided to acquire two US-based companies InvaGen Pharmaceuticals and Exelan Pharmaceuticals in an all cash deal valued at $550 million.

The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in the last twelve months ended June 2015. The acquisition will give the company scale in the US generics market through a wide range of product portfolio in central nervous system (CNS), cardiovascular system (CVS), anti-infectives, diabetes as well as other value added generics. InvaGen offers a large capacity manufacturing base in Hauppauge, New York,  and a skilled US-based R&D organization, Cipla’s first such presence in the US, the Mumbai-based pharma company said.

The acquisition of InvaGen pharmaceuticals also provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved over the next 4 years. In addition, InvaGen has filed five first-to-file products which represent a market size of around $8 billion in revenue by 2018. Dosage forms include immediate release, modified release and extended release tablets and capsules, Cipla said.

InvaGen has 3 units at Long Island, New York, with a total production capacity of 12 billion tablets and capsules per annum and an employee base of around 500.

Pharma deals


Acqusition of InvaGen to give Cipla scale in US generics market
Deal to strengthen Cipla with InvaGen’s 40 approved ANDAs, 32 marketed products and 30 pipeline products
Acquisition of Exelan to give Cipla access to govt and institutional markets in the US
Deal to strengthen Cipla with Exelan’s deep expertise, engagement and experienced
management team